Cultured Blood: How Lab-Grown Blood Could Change Medicine
Discover how cultured blood is produced, how stem cells create red blood cells, clinical trial progress, potential benefits and future medical applications.
Few areas of modern medical science hold more transformative potential than the development of cultured blood — laboratory-grown red blood cells produced from stem cells under carefully controlled conditions. As global blood donation demand continues to evolve and certain patient groups face persistent challenges with donor matching, researchers across the UK and internationally are investigating whether it may one day be possible to manufacture red blood cells outside the human body.
This article explores what cultured blood actually is, how it is produced, where current research stands, and what the future may realistically hold — while being clear about what remains experimental and what is established clinical practice.
A quick note on terminology: Some readers may arrive here searching for a blood culture test — a standard microbiology procedure used to detect bacterial or fungal infections in the bloodstream. That is an entirely different subject. This article focuses specifically on cultured blood, meaning laboratory-grown red blood cells produced from stem cells. The two should not be confused.
What Is Cultured Blood?
Cultured blood refers to red blood cells that have been grown in a laboratory setting using stem cells as a starting material. These cells are cultivated under controlled biological conditions designed to replicate aspects of natural red blood cell development. Unlike conventionally donated blood, cultured red blood cells are not collected from donors but produced through a scientific manufacturing process.
It is important to clarify what cultured blood is — and what it is not. Researchers are currently focused on producing red blood cells (erythrocytes) in the laboratory. This is not the same as manufacturing complete human blood, which also contains white blood cells, platelets, plasma proteins and many other components. Cultured red blood cells represent one component of blood, produced for specific research and potential transfusion investigation purposes.
Scientists are investigating this technology for several reasons: to explore whether lab-grown cells could supplement donated blood supplies, to research potential solutions for patients with rare blood types that are difficult to match, and to advance fundamental understanding of human haematopoiesis — the biological process by which blood cells are formed.
How Is Cultured Blood Made?
The production of cultured red blood cells is a complex, multi-stage scientific process. Here is a simplified overview of how researchers approach it:
- Stem cell sourcing: Scientists begin with haematopoietic stem cells — cells capable of developing into blood cell types. These may be sourced from adult peripheral blood, umbilical cord blood, or induced pluripotent stem cells (iPSCs) reprogrammed from adult cells.
- Cell selection and preparation: Appropriate stem cells are isolated and prepared for laboratory culture.
- Laboratory culture: Cells are placed in a controlled growth environment containing specific nutrients, growth factors and signalling proteins that guide development.
- Differentiation: The stem cells are stimulated to differentiate along the erythroid pathway, progressively becoming red blood cell precursors.
- Maturation: Precursor cells mature through several developmental stages, eventually producing reticulocytes and then mature red blood cells.
- Quality assessment: Researchers assess cell morphology, oxygen-carrying capacity, membrane integrity and functional characteristics.
- Research preparation: Cultured cells may then be prepared for laboratory experiments or, in advanced research settings, for use in carefully monitored clinical studies.
Practical Insight: Producing fully functional, mature red blood cells in the laboratory is genuinely challenging. Red blood cell development in the human body takes place within the bone marrow in a highly orchestrated biological environment. Replicating this complexity outside the body — at scale, consistently and safely — represents a significant scientific and manufacturing challenge.
Why Are Scientists Developing Lab-Grown Blood?
The scientific motivations behind cultured blood research are both practical and humanitarian.
Global blood donation systems depend entirely on voluntary donors. While the NHS Blood and Transplant service and equivalent organisations worldwide work effectively to maintain supplies, demand fluctuates, some blood groups are chronically harder to source, and certain patient populations require highly specialised matching that routine donation cannot always reliably provide.
Key research motivations include:
- Supplementing blood supplies during periods of high demand or shortage.
- Improving access for patients with rare blood group antigens who may face transfusion-matching difficulties.
- Reducing transfusion reactions in patients who require long-term or repeated transfusions.
- Advancing scientific understanding of red blood cell biology and haematopoiesis.
It is essential to distinguish between a research objective and an established clinical benefit. These motivations represent the goals of ongoing investigation, not confirmed outcomes of treatment already available to patients.
Cultured Blood vs Donated Blood: A Scientific Comparison
| Feature | Donated Blood | Cultured Blood |
|---|---|---|
| Source | Human blood donors | Laboratory-grown cells from stem cells |
| Production | Blood collection and processing | Cell culture and biological development |
| Availability | Established transfusion supply | Limited to research settings |
| Blood matching | Compatibility testing required | Potential for specialised matching research |
| Clinical use | Established transfusion practice | Investigational applications only |
| Production challenges | Donor supply, storage and logistics | Scalability, manufacturing cost, consistency |
It is worth emphasising that cultured red blood cells would still require appropriate compatibility assessment and rigorous safety evaluation before any clinical use. The production method being different does not remove the requirement for matching and safety testing.
Artificial Blood vs Cultured Blood: An Important Distinction
These two terms are sometimes used interchangeably, but they describe fundamentally different things and should not be conflated.
Cultured blood refers specifically to living red blood cells grown from human stem cells in laboratory conditions. The cells produced are biological in nature and structurally similar to naturally occurring red blood cells.
Artificial blood is a broader and less precise term that may refer to several quite different experimental products:
- Haemoglobin-based oxygen carriers (HBOCs): Chemical or biological compounds designed to carry oxygen around the body, based on haemoglobin extracted from various sources.
- Perfluorocarbon (PFC) emulsions: Synthetic compounds capable of dissolving oxygen, investigated as potential oxygen-transport agents.
- Other synthetic oxygen carriers at various stages of laboratory or early clinical investigation.
None of these products contain living red blood cells. Some artificial blood products have been investigated in clinical research over several decades, with mixed results regarding safety and efficacy. Neither cultured blood nor artificial blood products are currently part of routine NHS transfusion practice.
Practical Insight: The term "artificial blood" is frequently misused in popular media. When reading about this subject, it is always worth identifying precisely what type of product is being described, as the science, risks and development stage differ considerably.
Cultured Red Blood Cells: Clinical Trials and UK Research
The most significant recent development in this field is the RESTORE trial, led by NHS Blood and Transplant in collaboration with the University of Bristol and other UK research partners. Published findings in The Lancet in 2023 represented the first-ever human clinical trial of laboratory-grown red blood cells.
In this landmark early-phase study, a small number of healthy volunteers received mini-transfusions of cultured red blood cells produced from donor stem cells. Early clinical findings suggested that the laboratory-grown cells survived at least as long as — and in some participants, longer than — standard donated red blood cells from the same donors. This is a scientifically important early observation, though researchers have been appropriately cautious in interpreting what this means for future clinical applications.
Key points about the RESTORE trial:
- It was a Phase 1 safety and feasibility study, not a large-scale efficacy trial.
- The volumes of cultured cells transfused were small — this was not a full therapeutic transfusion.
- Safety monitoring was a primary objective.
- Results are considered early but encouraging by transfusion researchers.
- Significantly more research is required before clinical applications could be considered.
Researchers involved in the RESTORE trial acknowledged that manufacturing cultured red blood cells at scale remains a substantial challenge and that the trial represented a proof-of-concept step rather than a pathway to immediate clinical use.
Practical Insight: Clinical trial registration is not the same as published results demonstrating benefit or safety. The RESTORE trial represents a genuinely important scientific milestone, but it is an early-phase study. It should be interpreted as a carefully conducted first step, not as confirmation that cultured blood is ready for routine clinical use.
How Long Do Cultured Red Blood Cells Last?
Red blood cell lifespan is a clinically important consideration in transfusion medicine. Standard donated red blood cells typically survive in the recipient’s circulation for approximately 120 days following transfusion, though storage conditions and other factors affect this.
One of the more intriguing early findings from the RESTORE trial was that cultured red blood cells — which are younger and more recently matured than stored donated cells — appeared to survive longer in circulation in the participants studied. Researchers hypothesised that this might be because freshly produced cells had not been aged by the storage process that donated blood necessarily undergoes.
However, it is important not to overstate this finding. The study involved a very small number of participants, and far more research is required to understand:
- Whether this lifespan advantage is consistent across different participants.
- Whether younger cultured cells perform comparably to donated cells in terms of oxygen delivery.
- What the clinical implications might be for patients requiring regular transfusions.
A fixed lifespan for all cultured red blood cells cannot be stated with scientific confidence at this stage of research.
Safety Considerations for Lab-Grown Red Blood Cells
The safety of any new biological product intended for human use requires extensive investigation. For cultured red blood cells, researchers must address several important questions:
- Cell maturity: Are the cells fully matured and functional, or do they retain characteristics of immature precursor cells?
- Manufacturing consistency: Can cells be produced to a consistent, reproducible standard across different production batches?
- Contamination control: Are the culture processes sufficiently controlled to prevent microbial or other contamination?
- Genetic stability: Do the cells maintain appropriate genetic characteristics throughout the culture process?
- Immune compatibility: How do recipients’ immune systems respond to transfused cultured cells?
- Long-term effects: What are the potential longer-term effects of receiving laboratory-grown cells?
Early clinical findings from the RESTORE trial did not identify unexpected safety signals in the small number of participants studied, which is an encouraging early observation. However, researchers have been clear that long-term safety data, larger study populations and further clinical investigation are all required before any conclusions about clinical safety can be drawn.
It would be scientifically inaccurate to claim that laboratory-grown cells are automatically safer than donated blood. Both involve biological products requiring rigorous safety assessment.
Can Cultured Blood Help People With Rare Blood Types?
This is one of the most scientifically compelling potential applications of cultured blood research.
Blood group compatibility extends far beyond the familiar ABO and Rhesus (RhD) systems. There are over 360 known blood group antigens. Patients with rare combinations of antigens — or those who lack common antigens — may be extremely difficult to match using conventional donated blood, particularly those requiring long-term or repeat transfusions, such as individuals with sickle cell disease or thalassaemia.
Researchers have proposed that if stem cells from donors with specific rare blood group profiles could be used to produce cultured red blood cells, it might be possible to create more precisely matched cells for these patients. This is a genuinely promising area of investigation, though it remains at an early research stage.
Matching and compatibility requirements would not disappear with cultured blood — they remain scientifically essential. What cultured blood research may eventually offer is greater precision in producing cells with specific antigen profiles that are currently very difficult to source from the donor pool.
Challenges in Mass Producing Cultured Blood
Despite encouraging early-stage research, the practical challenges involved in producing cultured red blood cells at any clinically meaningful scale are considerable:
- Volume requirements: A single therapeutic transfusion typically requires billions of red blood cells. Current laboratory methods produce far smaller quantities.
- Production cost: The cost of producing even small quantities of cultured cells in research conditions is substantially higher than the cost of processing donated blood.
- Manufacturing infrastructure: Scaling laboratory processes to industrial-level production would require significant investment in specialist facilities and equipment.
- Regulatory approval: Any product intended for clinical transfusion would require extensive regulatory review and approval by bodies such as the MHRA in the UK.
- Quality consistency: Ensuring every batch of produced cells meets consistent quality and safety standards across a large-scale manufacturing process is technically demanding.
- Storage and distribution: Logistics for transporting and storing cultured cells would need to be developed and validated.
These are not insurmountable barriers, but they represent the reason why cultured blood, even in an optimistic scenario, is likely many years away from any potential routine clinical application.
The Cost of Producing Cultured Blood in a Laboratory
Current estimates suggest that producing cultured red blood cells in research conditions costs significantly more per unit than processing donated blood through established transfusion services. The cost drivers include:
- Specialist stem cell sourcing and preparation.
- Expensive growth factors and culture media required to support cell development.
- Highly controlled laboratory infrastructure.
- Skilled scientific personnel.
- Quality assurance and testing at each stage of production.
- Research and regulatory compliance costs.
There is no commercially established price for cultured blood because it is not commercially available. Any cost estimates in circulation are based on research production costs and would not be representative of a hypothetical future scaled manufacturing environment. Researchers and economists working in this field suggest that significant technological advances in bioprocessing will be required before production costs could approach anything comparable to donated blood processing.
What Is the Future of Cultured Red Blood Cells in Medicine?
The future of cultured blood research is scientifically interesting, though it is important to maintain realistic expectations about timelines and applications.
Researchers are investigating several potential future directions:
- Specialised transfusion support for patients with rare blood types or complex matching requirements.
- Supplementing donated blood during periods of supply pressure, rather than replacing donation entirely.
- Research into disease-specific applications, including sickle cell disease and other haemoglobinopathies.
- Advances in stem cell biology that could reduce production costs and increase manufacturing efficiency.
- Development of standardised manufacturing platforms capable of producing cells at greater scale.
The NHS Blood and Transplant service and UK research institutions remain at the forefront of international efforts in this field. The RESTORE trial positioned the UK as a leader in early-phase clinical research into cultured red blood cells, and further research programmes are anticipated.
However, clinical applications for cultured red blood cells — if they are eventually validated — are most likely to remain specialised and targeted rather than replacing the donated blood supply. Blood donation will remain critically important for the foreseeable future.
Supporting Your Health with Evidence-Based Screening
While cultured blood research represents the frontier of tomorrow’s medicine, understanding and monitoring your own health today remains one of the most effective things you can do. If you are interested in taking a proactive approach to your wellbeing, exploring a full health screening package can provide a valuable evidence-based snapshot of your current health status.
Health Screening Clinic offers a range of professional laboratory testing and health screening services, including a comprehensive Full Body MOT designed to give you meaningful, actionable health insights. For those with specific concerns, cardiovascular health screening is also available, providing important data about heart health and circulatory function.
Staying informed about developments in blood science — and taking responsibility for your own health through evidence-based screening — are complementary parts of a thoughtful approach to long-term wellbeing. You can explore all available health screening options to find what is appropriate for your individual circumstances.
Frequently Asked Questions About Cultured Blood
1. What is cultured blood?
Cultured blood refers to red blood cells that have been produced in a laboratory using stem cells as a starting material. Scientists cultivate these cells under controlled biological conditions to encourage them to mature into functional red blood cells. This is an emerging area of scientific research, not a routine clinical product. Cultured red blood cells are being investigated as a potential supplement to — not a replacement for — donated blood in transfusion medicine.
2. How is cultured blood made in a laboratory?
Cultured blood is made by isolating haematopoietic stem cells — typically from peripheral blood, cord blood or induced pluripotent stem cells — and placing them in a specialised laboratory culture environment. Growth factors and biological signals guide the cells through progressive stages of development until they mature into red blood cells. The process is scientifically complex, requiring precise control of conditions at each stage and rigorous quality assessment of the final cells.
3. Is cultured blood the same as artificial blood?
No. Cultured blood refers specifically to living red blood cells grown from human stem cells in laboratory conditions. Artificial blood is a broader term that may refer to synthetic or chemical oxygen carriers — such as haemoglobin-based oxygen carriers or perfluorocarbon compounds — which do not contain living cells. These are fundamentally different technologies at different stages of scientific development, and neither is currently part of routine clinical transfusion practice.
4. Can cultured red blood cells be used in transfusions?
Cultured red blood cells have been used in a small number of human participants in the RESTORE trial — an early-phase clinical study led by NHS Blood and Transplant and the University of Bristol. This was a carefully monitored research study, not routine clinical use. The volumes transfused were small, and the study was designed to assess safety and feasibility. Clinical transfusion applications remain under investigation and are not yet available outside research settings.
5. What are the potential benefits of lab-grown blood?
Researchers are investigating several potential benefits, including: supplementing blood supplies during periods of donor shortage; producing red blood cells with specific rare blood group antigen profiles for patients who are difficult to match; and potentially providing fresher cells that may survive longer in circulation. These are research objectives, not confirmed clinical benefits. Further investigation is required before any conclusions about benefits for patients can be drawn.
6. Can cultured blood help people with rare blood types?
This is one of the most promising potential applications of cultured blood research. Patients with rare blood group antigens can be extremely difficult to match using conventional donations. Researchers are investigating whether stem cells from donors with specific rare antigen profiles could be used to produce precisely matched cultured cells. This remains at an early investigational stage, and compatibility assessment would still be required regardless of how the cells are produced.
7. How long do cultured red blood cells survive?
Early findings from the RESTORE trial suggested that cultured red blood cells may survive at least as long as — and potentially longer than — standard donated cells in some participants. This may relate to the younger age of freshly produced cells compared with stored donated blood. However, this is an early observation from a small study and cannot be generalised as an established fact. Much more research is required to understand the lifespan of cultured cells across diverse populations.
8. Are cultured red blood cells safe?
Early-phase clinical research, including the RESTORE trial, did not identify unexpected safety concerns in the small number of participants studied. This is an encouraging early finding, but it is not sufficient to conclude that cultured red blood cells are safe for broader clinical use. Safety assessment must include larger populations, longer follow-up periods, manufacturing consistency evaluation and regulatory review. Safety claims for any investigational biological product must be treated with appropriate scientific caution.
9. What are the main challenges in producing cultured blood at scale?
The principal challenges include: producing sufficient cell volumes for therapeutic transfusions (which require billions of red blood cells per unit); the high cost of laboratory production compared to processed donated blood; the complexity of scaling laboratory processes to consistent industrial-scale manufacture; regulatory approval requirements; and ensuring quality consistency across different production batches. These barriers mean that any routine clinical application, even in an optimistic scenario, is likely many years away.
10. Is cultured blood available in the UK?
Cultured blood is not available as a routine clinical product in the UK or anywhere else in the world. It has been used in a small number of research participants in the early-phase RESTORE clinical trial, which was conducted by NHS Blood and Transplant and UK university partners. Outside of authorised research settings, cultured red blood cells are not available for clinical transfusion. Donated blood through NHS Blood and Transplant remains the established standard for transfusion medicine.